DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and international markets, beating consensus expectations and pairing this with guidance ...
Medical Device Network on MSN
JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth
Dexcom achieved FY25 revenues of around $4.66bn, corresponding to a 16% uplift over FY24.
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch ...
In 2020, Dexcom recorded a new high of $1.9 billion in revenue, prompting CEO Kevin Sayer to declare it the diabetes devicemaker’s “best year ever.” The company then proceeded to outstrip that total ...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results